1. ALLA AKTIER
  2. NYHETER
  3. Q-LINEA

Q-Linea

Nyheter Q-Linea Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Invitation to presentation of Q-linea’s Interim report Q2-2023 on July 13, 2023

Q-linea AB (publ) (Nasdaq Stockholm: QLINEA), to publish the company’s Interim report for the period January – June 2023 on Thursday 13 July 2023, at 07:30 a.m. (CEST).

Q-linea invites to an audiocast with teleconference (in English) or webcast for investors, analysts and media on July 13, 2023, at 13:00 – 14:00 p.m. (CEST).

Jonas Jarvius, CEO, and Christer Samuelsson, CFO/IR, to present Q-linea and comment on the Interim report followed by a Q&A-session.

If you wish to participate via the webcast, go to the link:
https://ir.financialhearings.com/q-linea-q2-2023
Via the webcast, there is an opportunity to ask written questions.

If you wish to verbally ask questions via conference call, register via the link:
https://conference.financialhearings.com/teleconference/?id=200818
After registration, you will receive a phone number and a conference ID to log into the conference. Via the telephone conference, there is an opportunity to ask questions verbally.

For more information, please contact:

Jonas Jarvius, CEO, Q-linea AB
Jonas.Jarvius@qlinea.com
+46 (0) 70-323 77 60

Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Attachments

Invitation to presentation of Q-linea’s Interim report Q2-2023 on July 13, 2023

Datum 2023-07-07, kl 16:42
Källa MFN
Bifogade filer
Invitation to presentation of Q-linea’s Interim report Q2-2023 on July 13, 2023